Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

By LabMedica International staff writers
Posted on 15 Jul 2025

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. More...

Traditional methods for evaluating myeloma treatment often require large cell samples, complex preparation, and time-intensive measurements, making it challenging to monitor individual patient responses quickly and accurately. As treatment effectiveness can vary from patient to patient, it’s crucial to assess how cancer cells are responding to therapy in real-time. Now, researchers have developed a novel method to track cancer treatment responses in individual cells without the need for dyes or labels, providing faster and more precise insights into treatment effectiveness.

The mid-infrared optoacoustic microscopy (MiROM) technology, developed by researchers from Helmholtz Munich (Munich, Germany) and the Technical University of Munich (Munich, Germany), can track treatment responses in individual cancer cells without the need for dyes or labels. This technology uses mid-infrared light to detect molecular vibrations in proteins, which helps to identify structural changes such as protein misfolding, a key indicator of myeloma treatment response.

MiROM works by capturing ultrasound waves generated when proteins absorb infrared light, causing a localized temperature increase. This approach enables real-time visualization of protein changes inside living cells, allowing for more personalized treatment of multiple myeloma patients. The researchers demonstrated MiROM’s ability to analyze individual cells with minimal sample preparation, providing fast insights into how treatments impact protein structures at the cellular level.

The MiROM technology was tested and validated by applying it to living myeloma cells. It successfully detected protein misfolding and apoptosis, or programmed cell death, which are key indicators of whether cancer treatments are working or if drug resistance is developing. Published in Lancet Healthy Longevity, the findings suggest that MiROM can provide near-instantaneous assessments of cancer treatment effectiveness, paving the way for more personalized therapy adjustments.

Beyond myeloma, MiROM shows potential for diagnosing other diseases related to protein misfolding, such as Alzheimer’s and Parkinson’s. Future research will focus on optimizing the technology for faster imaging and enhancing its sensitivity for broader clinical applications, including drug screening, diagnostics, and home-based patient monitoring.

“We envision the use of MiROM in drug screening, diagnostic tests and home-based patient monitoring,” said Prof. Vasilis Ntziachristos, a senior investigator in the study.

Related Links:
Helmholtz Munich
Technical University of Munich


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Portable Electronic Pipette
Mini 96
Laboratory Software
ArtelWare
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: LungCanSeek demonstrated an overall sensitivity of 83.5% and specificity of 90.3% in detecting lung cancer (Photo courtesy of AdobeStock)

New Blood Test Offers Affordable and Accurate Early Detection of Lung Cancer

Lung cancer remains the leading cause of cancer-related deaths worldwide, largely because most cases are diagnosed at advanced stages when treatment options are limited. Early detection significantly improves... Read more

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The TriVerity IVD test includes the TriVerity cartridge and the Myrna instrument (Photo courtesy of Inflammatix)

Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients

When a patient enters the emergency department in critical condition, clinicians must rapidly decide whether the patient has an infection, whether it is bacterial or viral, and whether immediate treatment... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.